Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

NCT03700476 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

425

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Neoplasms

Interventions

DRUG: Sintilimab
DRUG: Gemcitabine
DRUG: Cisplatin
RADIATION: intensity-modulated radiotherapy

Sponsor

Sun Yat-sen University

Collaborators

[object Object]